119
Participants
Start Date
October 31, 2011
Primary Completion Date
February 28, 2013
Study Completion Date
February 28, 2013
Placebo
Placebo solution for injection, administered as subcutaneous injections
Olokizumab 60 mg
Olokizumab 60 mg solution for injection, administered as subcutaneous injections
Olokizumab 120 mg
Olokizumab 120 mg solution for injection, administered as subcutaneous injections
Olokizumab 240 mg
Olokizumab 240 mg solution for injection, administered as subcutaneous injections
102, Chiba
114, Fukuoka
115, Fukuoka
113, Hiroshima
120, Kakogawa
118, Kumamoto
116, Kurume
121, Matsuyama
122, Matsuyama
107, Nagaoka
110, Nagoya
103, Narita
112, Okayama
119, Ōita
100, Sapporo
117, Sasebo
124, Tokorozawa
123, Tokyo
101, Tomakomai
108, Tonami
111, Tsu
105, Yokohama
104, Yotukaido
200, Daejeon
201, Junggu
202, Seongdong-gu
203, Seoul
204, Seoul
303, Changhua
304, Dalin-Town
305, Hualien City
300, Kaohsiung City
301, Taichung
306, Taichung
307, Taichung
302, Taipei
308, Taipei
309, Taipei
310, Taipei
UCB Japan Co. Ltd.
INDUSTRY